239 related articles for article (PubMed ID: 29562115)
1. Development of New Bexarotene-loaded Mesoporous Silica Systems for Topical Pharmaceutical Formulations.
Vasile A; Ignat M; Zaltariov MF; Sacarescu L; Stoleriu I; Draganescu D; Dumitras M; Ochiuz L
Acta Chim Slov; 2018 Mar; 65(1):97-107. PubMed ID: 29562115
[TBL] [Abstract][Full Text] [Related]
2. Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs.
Li T; Geng T; Md A; Banerjee P; Wang B
Colloids Surf B Biointerfaces; 2019 Apr; 176():185-193. PubMed ID: 30616109
[TBL] [Abstract][Full Text] [Related]
3. Controlling drug release from mesoporous silica through an amorphous, nanoconfined 1-tetradecanol layer.
Mitran RA; Matei C; Berger D; Băjenaru L; Moisescu MG
Eur J Pharm Biopharm; 2018 Jun; 127():318-325. PubMed ID: 29524598
[TBL] [Abstract][Full Text] [Related]
4. The investigation of MCM-48-type and MCM-41-type mesoporous silica as oral solid dispersion carriers for water insoluble cilostazol.
Wang Y; Sun L; Jiang T; Zhang J; Zhang C; Sun C; Deng Y; Sun J; Wang S
Drug Dev Ind Pharm; 2014 Jun; 40(6):819-28. PubMed ID: 23594300
[TBL] [Abstract][Full Text] [Related]
5. Development of solid SEDDS, VII: Effect of pore size of silica on drug release from adsorbed self-emulsifying lipid-based formulations.
Gumaste SG; Serajuddin ATM
Eur J Pharm Sci; 2017 Dec; 110():134-147. PubMed ID: 28506870
[TBL] [Abstract][Full Text] [Related]
6. Molecular-level insight into hot-melt loading and drug release from mesoporous silica carriers.
Lizoňová D; Mužík J; Šoltys M; Beránek J; Kazarian SG; Štěpánek F
Eur J Pharm Biopharm; 2018 Sep; 130():327-335. PubMed ID: 30012403
[TBL] [Abstract][Full Text] [Related]
7. Modulating in vitro release and solubility of griseofulvin using functionalized mesoporous silica nanoparticles.
Jambhrunkar S; Qu Z; Popat A; Karmakar S; Xu C; Yu C
J Colloid Interface Sci; 2014 Nov; 434():218-25. PubMed ID: 25203914
[TBL] [Abstract][Full Text] [Related]
8. Electrosprayed mesoporous particles for improved aqueous solubility of a poorly water soluble anticancer agent: in vitro and ex vivo evaluation.
Sayed E; Karavasili C; Ruparelia K; Haj-Ahmad R; Charalambopoulou G; Steriotis T; Giasafaki D; Cox P; Singh N; Giassafaki LN; Mpenekou A; Markopoulou CK; Vizirianakis IS; Chang MW; Fatouros DG; Ahmad Z
J Control Release; 2018 May; 278():142-155. PubMed ID: 29605567
[TBL] [Abstract][Full Text] [Related]
9. Mesoporous Silica Molecular Sieve based Nanocarriers: Transpiring Drug Dissolution Research.
Pattnaik S; Pathak K
Curr Pharm Des; 2017; 23(3):467-480. PubMed ID: 27784249
[TBL] [Abstract][Full Text] [Related]
10. Supersaturation Potential of Ordered Mesoporous Silica Delivery Systems. Part 1: Dissolution Performance and Drug Membrane Transport Rates.
Dening TJ; Taylor LS
Mol Pharm; 2018 Aug; 15(8):3489-3501. PubMed ID: 29985627
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of mesoporous silica particles as drug carriers in hydrogels.
Lunter DJ
Pharm Dev Technol; 2018 Oct; 23(8):826-831. PubMed ID: 28826298
[TBL] [Abstract][Full Text] [Related]
12. Mesoporous silica formulation strategies for drug dissolution enhancement: a review.
McCarthy CA; Ahern RJ; Dontireddy R; Ryan KB; Crean AM
Expert Opin Drug Deliv; 2016; 13(1):93-108. PubMed ID: 26549623
[TBL] [Abstract][Full Text] [Related]
13. Antioxidant properties of probucol released from mesoporous silica.
Lau M; Giri K; Garcia-Bennett AE
Eur J Pharm Sci; 2019 Oct; 138():105038. PubMed ID: 31398394
[TBL] [Abstract][Full Text] [Related]
14. Nanostructure-loaded mesoporous silica for controlled release of coumarin derivatives: a novel testing of the hyperthermia effect.
Al-Kady AS; Gaber M; Hussein MM; Ebeid el-ZM
Eur J Pharm Biopharm; 2011 Jan; 77(1):66-74. PubMed ID: 20974253
[TBL] [Abstract][Full Text] [Related]
15. Aerosol-Assisted Synthesis of Tailor-Made Hollow Mesoporous Silica Microspheres for Controlled Release of Antibacterial and Anticancer Agents.
Poostforooshan J; Belbekhouche S; Shaban M; Alphonse V; Habert D; Bousserrhine N; Courty J; Weber AP
ACS Appl Mater Interfaces; 2020 Feb; 12(6):6885-6898. PubMed ID: 31967774
[TBL] [Abstract][Full Text] [Related]
16. Mesoporous silica materials: From physico-chemical properties to enhanced dissolution of poorly water-soluble drugs.
Maleki A; Kettiger H; Schoubben A; Rosenholm JM; Ambrogi V; Hamidi M
J Control Release; 2017 Sep; 262():329-347. PubMed ID: 28778479
[TBL] [Abstract][Full Text] [Related]
17. A novel strategy to design sustained-release poorly water-soluble drug mesoporous silica microparticles based on supercritical fluid technique.
Li-Hong W; Xin C; Hui X; Li-Li Z; Jing H; Mei-Juan Z; Jie L; Yi L; Jin-Wen L; Wei Z; Gang C
Int J Pharm; 2013 Sep; 454(1):135-42. PubMed ID: 23871738
[TBL] [Abstract][Full Text] [Related]
18. Interplay of Adsorption, Supersaturation and the Presence of an Absorptive Sink on Drug Release from Mesoporous Silica-Based Formulations.
Hate SS; Reutzel-Edens SM; Taylor LS
Pharm Res; 2020 Aug; 37(8):163. PubMed ID: 32754797
[TBL] [Abstract][Full Text] [Related]
19. Amino-functionalized mesoporous silica nanoparticles as efficient carriers for anticancer drug delivery.
He Y; Luo L; Liang S; Long M; Xu H
J Biomater Appl; 2017 Oct; 32(4):524-532. PubMed ID: 28776488
[TBL] [Abstract][Full Text] [Related]
20. Impact of surface area of silica particles on dissolution rate and oral bioavailability of poorly water soluble drugs: a case study with aceclofenac.
Kumar D; Sailaja Chirravuri SV; Shastri NR
Int J Pharm; 2014 Jan; 461(1-2):459-68. PubMed ID: 24368106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
